Results for: Sage Therapeutics

Sage Therapeutics has announced the discontinuation of further clinical development of its drug dalzanemdor for Alzheimer’s disease following disappointing results from the Phase 2 LIGHTWAVE study. The study failed to demonstrate a statistically significant difference in cognitive function between patients treated with dalzanemdor and those receiving placebo. This setback follows earlier failures in trials for dalzanemdor in Parkinson’s disease and the termination of a collaboration agreement with Biogen for another drug candidate, SAGE-324.

Sage Therapeutics’ experimental treatment for essential tremor, SAGE-324, has been dropped by its partner Biogen after a Phase II trial failed to meet its primary endpoint. Despite the setback, Sage Therapeutics will retain full ownership of SAGE-324 and explore potential alternative indications for the drug. Meanwhile, Sage Therapeutics and Biogen continue their collaboration on the depression drug Zurzuvae.